USA-based biotech Tokai Pharmaceuticals (Nasdaq: TKAI) suffered a seismic 79% drop in its share price on Tuesday after the company announced the discontinuation of the ARMOR3-SV trial.
This is the pivotal Phase III study comparing galeterone, Tokai’s lead drug candidate, to enzalutamide in the treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients whose prostate tumors express AR-V7.
The decision to halt the trial follows the recommendation made on Monday by the study’s independent Data Monitoring Committee (DMC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze